AVI BioPharma 2002 News Archive

December

Avi BioPharma and International Therapeutics Enter Research Agreement to Target HIV Virus December 18, 2002, Portland, Oregon
Avi Presents NeuGene Antisense Data Targeting Prostate Cancer At Scientific Conference December 12, 2002, Portland, Oregon
Avi BioPharma Completes Clinical Trials With NeuGene Antisense Targeting Drug Metabolism December 12, 2002, Portland, Oregon
Avi Announces Promising NeuGene Antisense Results Targeting Viruses December 5, 2002, Portland, Oregon

November

Clinical Trial Supports Further Study of AVI's NeuGene Antisense In Polycystic Kidney Disease Patients November 20, 2002, Portland, Oregon
Studies Support Targeted Systemic Delivery of NeuGene Antisense To Treat Coronary Arteries November 19, 2002, Portland, Oregon
Avi to Present at Paulson SmallCap Conference November 6, 2002, Portland, Oregon
Avi BioPharma Initiates New Round of Human Clinical Trials With NeuGene Antisense Targeting Drug Metabolism November 5, 2002, Portland, Oregon
Avi Biopharma Announces Third Quarter Financial Results November 5, 2002, Portland, Oregon

October

Avi's Combination Antisense Strategy Inhibits Tumor Growth In Human Prostate Cancer Models October 30, 2002, Portland, Oregon
Study Supports Topical Application of AVI's NeuGene Antisense October 29, 2002, Portland, Oregon
Avi BioPharma Confirms Availability of Additional Route Of Administration for NeuGene Antisense Drugs October 24, 2002, Portland, Oregon
Avi BioPharma Presents at 10th Anniversary Of BioPartnering Europe October 14, 2002, Portland, Oregon
Avi BioPharma Presents at UBS Warburg Global Life Sciences Conference October 4, 2002, Portland, Oregon
Avi Announces Positive Interim Results of Phase II Antisense Trial For Cardiovascular Restenosis October 1, 2002, Portland, Oregon

August

Avi Biopharma Announces Second Quarter Financial Results August 6, 2002, Portland, Oregon
Avi BioPharma to Extend Expiration Dates of AVIIW Warrants August 1, 2002, Portland, Oregon
Avi BioPharma Completes NeuGene Antisense Clinical Trial In Patients With Polycystic Kidney Disease August 1, 2002, Portland, Oregon

July

Promising Results of AVI BioPharma Colorectal Study Featured In Clinical Cancer Research July 24, 2002, Portland, Oregon
Avi BioPharma Demonstrates Effective Delivery of NeuGene Antisense Therapeutics July 11, 2002, Portland, Oregon

June

Avi BioPharma NeuGene Antisense Study Featured In Drug Metabolism and Disposition June 25, 2002, Portland, Oregon
Avi BioPharma Presents Effectiveness of NeuGene Antisense Agent In Inhibiting Prostate Cancer Cell Growth June 20, 2002, Portland, Oregon
Avi BioPharma Officers and Directors Complete Purchase Of Company's Common Stock June 19, 2002, Portland, Oregon

May

Avi BioPharma Names KPMG as Independent Public Accountant May 31, 2002, Portland, Oregon
Avi BioPharma to Present Avicine Pancreatic Cancer Survival Data At American Society of Clinical Oncology May 21, 2002, Portland, Oregon
Avi BioPharma Demonstrates Effectiveness of NeuGene Antisense Agents As Potential Antibiotics Targeting Calicivirus and E. Coli May 20, 2002, Portland, Oregon
Avi BioPharma to Present Novel Antisense Approach at Leading Interventional Cardiology Conference May 17, 2002, Portland, Oregon
Avi BioPharma Appoints Andrew J. Ferrara to Board Of Directors May 15, 2002, Portland, Oregon
Avi BioPharma Scientists Publish Results of Antisense Drug In Treating Cancer and Viral Infections May 14, 2002, Portland, Oregon
Avi BioPharma Demonstrates Effectiveness of Antisense Drug In Treating Symptoms of Polycystic Kidney Disease May 10, 2002, Portland, Oregon
Avi BioPharma Announces Clinical Study Results Providing the First Definitive Evidence of Antisense Efficacy in Humans May 7, 2002, Portland, Oregon
Avi BioPharma Announces First Quarter Financial Results May 7, 2002, Portland, Oregon
Avi BioPharma Announces Plans to Initiate Phase III Clinical Trial In Pancreatic Cancer With Avicine May 2, 2002, Portland, Oregon

April

Avi BioPharma Initiates Clinical Development Program For NeuGene Antisense Treatment of Coronary Artery Bypass Grafts April 29, 2002, Portland, Oregon
Avi BioPharma Scientist Presents Data Showing Novel Antisense Inhibits Gene Expression of Metabolic Enzyme in Human Liver April 23, 2002, Portland, Oregon
Avi BioPharma Scientist Presents Novel Antisense Approach For Prostate Cancer at AACR 93rd Annual Meeting April 9, 2002, Portland, Oregon

March

Avi BioPharma Completes $22 Million Private Financing March 26, 2002, Portland, Oregon
Avi BioPharma Announces Efficacy of Oral Administration Of Its Proprietary NeuGene Antisense Agents in Rats March 21, 2002, Portland, Oregon
Avi BioPharma Announces 2001 Fourth Quarter And Full Year Financial Results March 12, 2002, Portland, Oregon
Avi BioPharma to Extend Expiration Dates of AVIIW and AVIIZ Warrants March 5, 2002, Portland, Oregon
Avi BioPharma Scientists to Present Novel Antisense Approach For Prostate Cancer and Emerging Infectious Diseases at Conferences Worldwide March 4, 2002, Portland, Oregon

February

Avi BioPharma Executives to Speak at Roth Capital Partners and BIO CEO Investor Conferences February 19, 2002, Portland, Oregon
Avi BioPharma Obtains Worldwide Exclusive Rights To Important Viral Target February 12, 2002, Portland, Oregon
Avi BioPharma Opens GMP Manufacturing Plant For NeuGene Antisense Drugs for Clinical Trials and Commercialization February 5, 2002, Portland, Oregon

January

Avi BioPharma Names Waggener Edstrom Its PR Agency of Record January 31, 2002, Portland, Oregon
Avi BioPharma's President to Present Company Milestones at U.S. Bancorp Piper Jaffray Health Care Conference January 30, 2002, Portland, Oregon

About AVI BioPharma

RNA Platform Technology

Clinical Programs

Communication